tradingkey.logo

Evolus Inc

EOLS
View Detailed Chart
6.900USD
+0.050+0.73%
Close 12/26, 16:00ETQuotes delayed by 15 min
446.89MMarket Cap
LossP/E TTM

Evolus Inc

6.900
+0.050+0.73%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.73%

5 Days

-2.40%

1 Month

-1.99%

6 Months

-24.51%

Year to Date

-37.50%

1 Year

-37.78%

View Detailed Chart

TradingKey Stock Score of Evolus Inc

Currency: USD Updated: 2025-12-26

Key Insights

Evolus Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 52/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evolus Inc's Score

Industry at a Glance

Industry Ranking
52 / 158
Overall Ranking
130 / 4563
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
18.500
Target Price
+165.42%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Evolus Inc Highlights

StrengthsRisks
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 79.17% year-on-year.
Overvalued
The company’s latest PE is -7.59, at a high 3-year percentile range.
Held by PRFDX
Star Investor PRFDX holds 20.74K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.68.

Evolus Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Evolus Inc Info

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Ticker SymbolEOLS
CompanyEvolus Inc
CEOMoatazedi (David)
Websitehttps://www.evolus.com/

FAQs

What is the current price of Evolus Inc (EOLS)?

The current price of Evolus Inc (EOLS) is 6.900.

What is the symbol of Evolus Inc?

The ticker symbol of Evolus Inc is EOLS.

What is the 52-week high of Evolus Inc?

The 52-week high of Evolus Inc is 17.120.

What is the 52-week low of Evolus Inc?

The 52-week low of Evolus Inc is 5.710.

What is the market capitalization of Evolus Inc?

The market capitalization of Evolus Inc is 446.89M.

What is the net income of Evolus Inc?

The net income of Evolus Inc is -50.42M.

Is Evolus Inc (EOLS) currently rated as Buy, Hold, or Sell?

According to analysts, Evolus Inc (EOLS) has an overall rating of Buy, with a price target of 18.500.

What is the Earnings Per Share (EPS TTM) of Evolus Inc (EOLS)?

The Earnings Per Share (EPS TTM) of Evolus Inc (EOLS) is -0.909.
KeyAI